BlackRock Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlackRock Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.63M	Sell	78,719 -231	-0.3%	-$3.87K	﹤0.01%	2369
2016 Q3	$1.28M	Buy	78,950 +637	+0.8%	+$9.25K	﹤0.01%	2497
2016 Q2	$1.06M	Buy	78,313 +13,143	+20%	+$232K	﹤0.01%	2584
2016 Q1	$1.14M	Buy	65,170 +1,394	+2%	+$28.4K	﹤0.01%	2396
2015 Q4	$2.18M	Buy	63,776 +8,484	+15%	+$294K	﹤0.01%	2014
2015 Q3	$1.65M	Sell	55,292 -376	-0.7%	-$11.4K	﹤0.01%	2221
2015 Q2	$1.78M	Buy	55,668 +28,727	+107%	+$739K	﹤0.01%	2333
2015 Q1	$558K	Buy	26,941 +405	+2%	+$7K	﹤0.01%	2906
2014 Q4	$450K	Buy	26,536 +222	+0.8%	+$3.88K	﹤0.01%	3058
2014 Q3	$509K	Buy	26,314 +4,831	+22%	+$126K	﹤0.01%	2960
2014 Q2	$730K	Buy	21,483 +2,283	+12%	+$71.5K	﹤0.01%	2824
2014 Q1	$605K	Buy	+19,200	New	+$600K	﹤0.01%	2847

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock Investment Management's RVNC Position: Q4 2016 in Review

BlackRock Investment Management reduced its Revance Therapeutics, Inc. (RVNC) stake by 0.29% in Q4 2016, selling an estimated $3.87K and leaving 78,719 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2369.

BlackRock Investment Management first reported a position in RVNC in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.18M in Q4 2015. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

BlackRock Investment Management held 78,719 shares of Revance Therapeutics, Inc. worth $1.63M as of Q4 2016.
BlackRock Investment Management sold 231 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $3.87K.
Revance Therapeutics, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2369 holding.
BlackRock Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Revance Therapeutics, Inc. position peaked at $2.18M in Q4 2015.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.